Liquid Biopsy Newsletter
March 2026, Vol. 2
Dear Readers, dear Colleagues,
Liquid biopsy — the analysis of tumor DNA from a simple blood draw — is transforming cancer diagnostics. New studies, indications, and clinical data are published almost daily.
But here lies the problem. If you are an oncologist determining whether MRD testing could guide treatment decisions — where do you turn? If you are a patient wanting to understand what the evidence says for your cancer type — how do you find reliable, current answers?
Today, this information is scattered across hundreds of publications, conference abstracts, and clinical trial databases — with no single resource pulling it together in an accessible, structured way. This is the gap we set out to close.
That is why we created www.liquidbiopsyinfo.com.
www.liquidbiopsyinfo.com provides structured, evidence-based information on liquid biopsy applications — covering MRD detection and molecular profiling across more than 20 cancer types, grounded in peer-reviewed literature and clinical trial data.
We use AI to keep pace with the volume of new publications — and we know this requires expert oversight to meet the standards clinicians and patients deserve. That is why this is an open invitation.
If you work in oncology, liquid biopsy, or clinical research and you think this kind of resource matters I would genuinely value your perspective.
I am also excited to share that our study "MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay" has just been published in Blood, a leading hematology journal. The online-first PDF is available now: https://liqomics.com/en/publications/ This study adds to the growing evidence base for ctDNA-based MRD assessment in Hodgkin lymphoma and beyond. We will discuss the implication of this new study in a future newsletter.
Your opinion is important to us. Please let us know how helpful you find www.liquidbiopsyinfo.com What should be improved? Write to us: newsletter@liqomics.com
We look forward to your thoughts and feedback — and to continuing this conversation with you. Warm regards,
Sven Borchmann MD, PHD, LIQOMICS founder and Managing Director
